A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation

Trial Profile

A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Azacitidine (Primary) ; Cytarabine (Primary) ; FT 2102 (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors FORMA Therapeutics
  • Most Recent Events

    • 06 Dec 2017 Phase of trial changed from phase 1/1b to phase 1/2, with addition of Cytarabine and addition of efficacy endpoint
    • 06 Dec 2017 Planned number of patients changed from 76 to 400.
    • 06 Dec 2017 Planned End Date changed from 1 Jul 2018 to 1 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top